ImmuPharma (LON:IMM) Stock Price Up 13.6% - Here's Why

Key Points

• ImmuPharma's stock price surged by 13.6% during mid-day trading, reaching a high of GBX 14.45 after closing at GBX 11.50 the previous day.
• The trading volume increased significantly, with approximately 24.7 million shares exchanged, marking a 189% rise compared to the average daily volume.
• ImmuPharma reported a net margin of 3,519.56% and a negative return on equity of -131.41% in their latest earnings announcement.

ImmuPharma plc (LON:IMM - Get Free Report) shares rose 13.6% during mid-day trading on Thursday . The company traded as high as GBX 14.45 ($0.20) and last traded at GBX 13.06 ($0.18). Approximately 24,707,008 shares were traded during mid-day trading, an increase of 189% from the average daily volume of 8,537,366 shares. The stock had previously closed at GBX 11.50 ($0.16).

ImmuPharma Trading Up 13.4%

The stock's 50-day moving average is GBX 3.87 and its 200-day moving average is GBX 3.15. The stock has a market cap of £65.16 million, a P/E ratio of -1,465.17 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, equities analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.